Alfasigma Partners with Innovative Molecules to Develop Groundbreaking HSV Treatment Adibelivir Alfasigma has secured exclusive rights to develop Adibelivir, aiming to combat HSV encephalitis, a rare and life-threatening disease.

Alfasigma Partners with Innovative Molecules to Develop Groundbreaking HSV Treatment Adibelivir #Italy #Bologna #Alfasigma #Adibelivir #HSV_Encephalitis